Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05408936

SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

Sponsor: University of Patras

View on ClinicalTrials.gov

Summary

Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit. A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.

Official title: Study of the Mechanisms Leading to Increased Hemoglobin Levels and of the Cardiorenal Response in Type 2 Diabetic Patients With Recent Initiation of SGLT2 Inhibitors.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

80

Start Date

2022-06-03

Completion Date

2024-06-01

Last Updated

2024-05-14

Healthy Volunteers

No

Interventions

DRUG

SGLT2 inhibitor

Patients receive an SGLT2 inhibitor as part of theirn routine care.

Locations (1)

University Hospital of Patras

Pátrai, Greece